CV Sciences, Inc. in brief
CV Sciences, Inc. is a listed company in the Pharmaceutical industry, based in San Diego, California, USA. It was founded in 2010. Its last known market value was $20 M (January 2022); there is no current figure. In the year to December 2025 it had sales of $14 M and a net loss of $1 M. It employs about 44 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CV Sciences, Inc.
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business to business-to-consumer.
Our +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe status.
From the company's annual report filed with the US SEC: read the report
CV Sciences, Inc. timeline
- 2010
- 🏁· approximateFounded
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- ✎Renamed CannaVEST Corp.Formerly Foreclosure Solutions, Inc..
- 2016
- ✎Renamed CV Sciences, Inc.Formerly CannaVEST Corp..
- 2019
- 💰Record revenue of $54 millionFY2019, the highest of the 8 years on record.
Events of CV Sciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,677 (Jan 2020) · #4,094 (Jan 2021) · #5,391 (Jan 2022)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -15.8%
- Operating margin
- -3.4%
- Return on equity
- -136.7%
- Liabilities / assets
- 78.9%
- Net debt
- $1M
- Revenue growth
- -12.2%
- R&D / revenue
- 0.9%
- Revenue per employee
- $313 K
- Profit per employee
- $-22 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $14M | -12.2% | $-0M | $-1M | -7.0% |
| Dec 2024 | $16M | -1.9% | $-2M | $-2M | -15.2% |
| Dec 2023 | $16M | -1.2% | $3M | $3M | 19.4% |
| Dec 2022 | $16M | -19.2% | $-7M | $-8M | -50.7% |
| Dec 2021 | $20M | -17.9% | $-18M | $-16M | -77.6% |
| Dec 2020 | $24M | -54.5% | $-23M | $-22M | -91.2% |
| Dec 2019 | $54M | +11.3% | $-17M | $-17M | -30.9% |
| Dec 2018 | $48M | — | $10M | $10M | 20.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-0M | $0M | $-1M | $-0.01 | — |
| Dec 2024 | $-1M | $0M | $-1M | $-0.01 | — |
| Dec 2023 | $2M | $0M | $2M | $0.02 | — |
| Dec 2022 | $-2M | $0M | $-2M | $-0.07 | — |
| Dec 2021 | $-7M | $0M | $-8M | $-0.14 | — |
| Dec 2020 | $-7M | $1M | $-8M | $-0.22 | — |
| Dec 2019 | $-2M | $1M | $-3M | $-0.17 | — |
| Dec 2018 | $13M | $1M | $12M | $0.09 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $3M (-7.1% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 26, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations · Other events
- Jun 4, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 15, 2026DEF 14AProxy statement
- Apr 10, 20268-KCurrent reportMaterial agreement · New financial obligation
- Mar 26, 202610-KAnnual report · period to Dec 2025
- Mar 26, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Mar 10, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
Official filings of CV Sciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $14 M
- Operating income
- $-0 M
- Net income
- $-1 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $5 M
- Total equity
- $1 M
As of December-2025
Insider trading at CV Sciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Charlie E. Cheever III10% owner | Buy | +383,205 | $0.010 | $4 K | 32.09 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +1.98 M | $0.010 | $20 K | 31.71 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +500,000 | $0.010 | $5 K | 29.73 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +1.08 M | $0.010 | $11 K | 29.23 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +1.50 M | $0.010 | $15 K | 28.15 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +94,854 | $0.020 | $2 K | 26.65 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +108,000 | $0.020 | $2 K | 26.55 M | Form 4 |
| filed | Charlie E. Cheever III10% owner | Buy | +1.73 M | $0.020 | $35 K | 26.45 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
CV Sciences, Inc. scorecard#
Passes 3 of the 15 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (1 of 6). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 6
- ✗Revenue grew in the newest year-12.2%Revenue down 12.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-5.2%-5.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-5.2%-5.2% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-0.01 vs -0.01Diluted EPS -0.01 in fiscal 2025 against -0.01 the year before (report's currency).
- ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against -$22 M in 2020.
- ✗Revenue rose in at least four of the last five years0 of 5Revenue rose in 0 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-3.4%-3.4% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-58.7%-58.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-3.4%-3.4% in fiscal 2025 against -42.3% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.0×Current ratio 1.03 at the end of fiscal 2025.
- ✗Debt below equity1.1×Debt to equity 1.12 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.9%Diluted shares up 4.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from CV Sciences, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -3.4% | 1.8% | |
| Net margin | -7.0% | -1.5% | |
| Return on equity | -58.7% | -0.9% | |
| Revenue growth, 3 years a year | -5.2% | 2.5% | |
| Revenue growth | -12.2% | 7.3% | |
| Debt to equity | 1.12× | 0.66× |
6of 9on the Piotroski tests of financial strength
- Revenue fell 12.2% against the year before.
- Net loss of $1 million.
- Free cash flow was negative: -$1 million.
CV Sciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 13,789−12.2%100% | 15,705−1.9%100% | 16,004−1.2%100% | 16,205−19.2%100% | 20,048−17.9%100% | 24,429−54.5%100% | 53,696+11.3%100% | 48,244+133%100% | 20,679r20,679+87.0%100% | 11,061—100% | |
| Cost of revenue | 7,037−17.6%51.0% | 8,537−4.3%54.4% | 8,919−16.3%55.7% | 10,655−6.8%65.8% | 11,432−14.8%57.0% | 13,420−27.9%54.9% | 18,608+29.5%34.7% | 14,366+132%29.8% | 6,190r6,191+52.4%29.9% | 4,063—36.7% | |
| Gross profit | 6,752−5.8%49.0% | 7,168+1.2%45.6% | 7,085+27.7%44.3% | 5,550−35.6%34.2% | 8,616−21.7%43.0% | 11,009−68.6%45.1% | 35,088+3.6%65.3% | 33,878+134%70.2% | 14,489r14,489+107%70.1% | 6,998—63.3% | |
| Research and development | 122+3.4%0.9% | 118−21.9%0.8% | 151−50.8%0.9% | 307−74.1%1.9% | 1,185−59.7%5.9% | 2,943−49.9%12.0% | 5,877+212%10.9% | 1,885+160%3.9% | 724r724−37.5%3.5% | 1,159—10.5% | |
| Selling, general and administrative | 7,622−17.5%55.3% | 9,240−5.2%58.8% | 9,745−19.4%60.9% | 12,090−53.3%74.6% | 25,877−15.6%129% | 30,658−34.0%125% | 46,451+114%86.5% | 21,746+34.3%45.1% | 16,193r16,252+23.3%78.3% | 13,130—119% | |
| Selling and marketing | 2,803−11.5%20.3% | 3,166+3.3%20.2% | 3,065—19.2% | — | — | — | — | — | — | — | |
| General and administrative | 3,153−20.9%22.9% | 3,986+6.6%25.4% | 3,740−69.1%23.4% | 12,090−53.3%74.6% | 25,877−15.6%129% | 30,658−34.0%125% | 46,451+114%86.5% | 21,746+34.3%45.1% | 16,193r16,252+23.3%78.3% | 13,130—119% | |
| Operating expenses | — | — | — | 12,397−54.2%76.5% | 27,062−19.5%135% | 33,601−35.8%138% | 52,328+121%97.5% | 23,631+22.1%49.0% | 19,349r19,349−3.6%93.6% | 20,071r14,289—181% | |
| Operating income | −470—−3.4% | −2,190−165%−13.9% | 3,360—21.0% | −6,847—−42.3% | −18,446—−92.0% | −22,592—−92.5% | −17,240−268%−32.1% | 10,247—21.2% | −4,860r−4,860—−23.5% | −13,074—−118% | |
| Interest expense and finance costs | 517+144%3.7% | 212—1.3% | — | 600+1479%3.7% | 38—0.2% | — | — | 153−69.8%0.3% | 507r506−53.3%2.5% | 1,087—9.8% | |
| Net interest income | — | — | — | −1,541—−9.5% | −140—−0.7% | −9.0−160%−0.0% | 15—0.0% | −153—−0.3% | — | — | |
| Other non-operating income (expense) | −479—−3.5% | −212—−1.3% | −264—−1.6% | −1,541—−9.5% | — | — | — | −153—−0.3% | −519r−519—−2.5% | −1,068—−9.7% | |
| Income before tax | −949—−6.9% | −2,402−178%−15.3% | 3,096—19.3% | −8,261—−51.0% | −15,641—−78.0% | −22,601—−92.5% | −17,225−271%−32.1% | 10,094—20.9% | −5,379r−5,379—−26.0% | −14,141—−128% | |
| Income tax | 9.0—0.1% | −8.0—−0.1% | −6.0—−0.0% | −47—−0.3% | −87—−0.4% | −317—−1.3% | −615−761%−1.1% | 93—0.2% | −482r−482—−2.3% | 0—0.0% | |
| Net income attributable to shareholders | −958—−6.9% | −2,394−177%−15.2% | 3,102—19.4% | −8,214—−50.7% | −15,554—−77.6% | −22,284—−91.2% | −16,610−266%−30.9% | 10,001—20.7% | −4,897r−4,897—−23.7% | −14,141—−128% | |
| Earnings per share, basic | -0.01—— | -0.01−150%— | 0.02—— | -0.07—— | -0.14—— | -0.22—— | -0.17−255%— | 0.11—— | -0.06r-0.05—— | -0.27r-0.26—— | |
| Earnings per share, diluted | -0.01—— | -0.01−150%— | 0.02—— | -0.07—— | -0.14—— | -0.22—— | -0.17−289%— | 0.09—— | -0.06r-0.05—— | -0.27r-0.26—— | |
| Shares, weighted average (basic) | 184+4.9%— | 176+14.1%— | 154+11.5%— | 138+28.0%— | 108+7.9%— | 100+2.1%— | 98+6.5%— | 92+14.3%— | 80—— | — | |
| Shares, weighted average (diluted) | 184+4.9%— | 176+14.0%— | 154+11.5%— | 138+28.0%— | 108+7.9%— | 100+2.1%— | 98−14.5%— | 114+42.3%— | 80r91+52.7%— | 53—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 278−38.8%4.0% | 454−65.5%5.7% | 1,317+116%14.3% | 611−55.6%4.8% | 1,375−65.8%7.6% | 4,024−55.8%13.1% | 9,107−28.2%17.3% | 12,684+530%34.4% | 2,013r2,013+157%8.9% | 782—4.2% | |
| Receivables | 402−23.0%5.8% | 522+21.1%6.6% | 431−43.7%4.7% | 766−62.5%6.0% | 2,041+81.3%11.3% | 1,126−48.3%3.7% | 2,177−34.8%4.1% | 3,340+122%9.1% | 1,507r1,508+318%6.6% | 360—1.9% | |
| Inventory | 4,087−16.5%58.7% | 4,897−13.4%61.8% | 5,655−13.8%61.5% | 6,563−23.9%51.5% | 8,624−2.4%47.7% | 8,840−11.3%28.9% | 9,971+39.8%18.9% | 7,132+153%19.3% | 2,823r2,823−1.0%12.4% | 2,852—15.3% | |
| Other current assets | 366−1.1%5.3% | 370−30.8%4.7% | 535−83.2%5.8% | 3,190+48.6%25.0% | 2,146−9.5%11.9% | 2,372−77.6%7.7% | 10,611+1714%20.1% | 585+46.2%1.6% | 400r400—1.8% | 0r551—0.0% | |
| Current assets | 5,133−17.8%73.7% | 6,243−21.4%78.8% | 7,938−28.7%86.3% | 11,130−21.5%87.4% | 14,186−15.9%78.5% | 16,863−47.9%55.1% | 32,367+27.1%61.4% | 25,466+221%69.0% | 7,935r7,935+64.6%34.9% | 4,821—25.9% | |
| Property, plant and equipment | 344−13.8%4.9% | 399+5.3%5.0% | 379−34.1%4.1% | 575−66.5%4.5% | 1,717−40.3%9.5% | 2,877−20.4%9.4% | 3,615+27.1%6.9% | 2,844+36.5%7.7% | 2,084r2,083+759%9.2% | 243—1.3% | |
| Right-of-use (leased) assets | 347+269%5.0% | 94−43.7%1.2% | 167−39.3%1.8% | 275—2.2% | 0−100%0.0% | 3,057−64.9%10.0% | 8,709—16.5% | 0—0.0% | — | — | |
| Goodwill | 1,015+4.5%14.6% | 971+184%12.2% | 342—3.7% | 0—0.0% | 0−100%0.0% | 2,7880.0%9.1% | 2,7880.0%5.3% | 2,7880.0%7.6% | 2,788r2,788−0.0%12.3% | 2,788—15.0% | |
| Other intangible assets | 76−18.3%1.1% | 93+19.2%1.2% | 78−68.9%0.8% | 251−83.1%2.0% | 1,485−60.2%8.2% | 3,730−1.0%12.2% | 3,766−0.9%7.1% | 3,801−0.9%10.3% | 3,836r3,836−0.9%16.9% | 3,872—20.8% | |
| Non-current assets | — | — | — | — | — | — | — | — | 14,775+7.3%65.1% | 13,771—74.1% | |
| Total assets | 6,962−12.2%100% | 7,927−13.8%100% | 9,200−27.8%100% | 12,736−29.5%100% | 18,066−41.0%100% | 30,625−41.9%100% | 52,687+42.8%100% | 36,902+62.5%100% | 22,710r22,710+22.1%100% | 18,592—100% | |
| Accounts payable | 1,044−45.8%15.0% | 1,925−16.6%24.3% | 2,309+1.1%25.1% | 2,284−13.0%17.9% | 2,624+56.5%14.5% | 1,677+3.7%5.5% | 1,617+29.9%3.1% | 1,245+83.6%3.4% | 678r678+29.5%3.0% | 524—2.8% | |
| Debt due within a year | 1,262+86.4%18.1% | 677—8.5% | — | — | 310−85.7%1.7% | 2,174—7.1% | — | — | — | — | |
| Current liabilities | 5,000−18.2%71.8% | 6,109−0.1%77.1% | 6,115−54.1%66.5% | 13,314−7.9%105% | 14,461+0.9%80.0% | 14,336+8.6%46.8% | 13,196+200%25.0% | 4,392+31.7%11.9% | 3,336r3,336+6.0%14.7% | 3,149—16.9% | |
| Long-term debt | 387—5.6% | 0—0.0% | — | — | 0−100%0.0% | 1,453—4.7% | — | — | — | — | |
| Lease liabilities (non-current) | 100+426%1.4% | 19−67.2%0.2% | 58−69.1%0.6% | 188—1.5% | 0−100%0.0% | 3,467−63.6%11.3% | 9,517—18.1% | 0—0.0% | — | — | |
| Total liabilities | 5,494−10.4%78.9% | 6,132−2.6%77.4% | 6,297−53.4%68.4% | 13,513−7.0%106% | 14,523−25.2%80.4% | 19,413−17.5%63.4% | 23,540+247%44.7% | 6,786+7.2%18.4% | 6,329r6,329+17.6%27.9% | 5,384—29.0% | |
| Retained earnings | −87,939—−1263% | −86,981—−1097% | −84,587—−919% | −87,689—−689% | −79,475—−440% | −63,921—−209% | −41,637—−79.0% | −25,027—−67.8% | −35,028r−35,028—−154% | −30,131—−162% | |
| Shareholders' equity | 1,468−18.2%21.1% | 1,795−38.2%22.6% | 2,903—31.6% | −777−122%−6.1% | 3,543−68.4%19.6% | 11,212−61.5%36.6% | 29,147−3.2%55.3% | 30,116+83.8%81.6% | 16,381r16,381+24.0%72.1% | 13,208r13,208—71.0% | |
| Total liabilities and equity | 6,962−12.2%100% | 7,927−13.8%100% | 9,200−27.8%100% | 12,736−29.5%100% | 18,066−41.0%100% | 30,625−41.9%100% | 52,687+42.8%100% | 36,902+62.5%100% | 22,710r22,710+22.1%100% | 18,592—100% | |
| Shares outstanding | 1840.0%— | 184+14.0%— | 162+6.3%— | 152+35.2%— | 112+11.7%— | 101+1.3%— | 99+4.7%— | 95+4.9%— | 91r91+57.1%— | 58—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 192−42.5%1.4% | 334+42.1%2.1% | 235−76.3%1.5% | 992−14.0%6.1% | 1,153+32.2%5.8% | 872+21.8%3.6% | 716+38.0%1.3% | 519+184%1.1% | 183r183−82.6%0.9% | 1,053—9.5% | |
| Share-based compensation | 497+92.6%3.6% | 258+18.3%1.6% | 218−78.4%1.4% | 1,009−68.6%6.2% | 3,210−17.3%16.0% | 3,881−30.6%15.9% | 5,589+91.1%10.4% | 2,925−14.4%6.1% | 3,419r3,420+25.1%16.5% | 2,733—24.7% | |
| Cash from operating activities | −407—−3.0% | −861−138%−5.5% | 2,253—14.1% | −1,885—−11.6% | −7,485—−37.3% | −7,300—−29.9% | −2,227−118%−4.1% | 12,559+247%26.0% | 3,615r3,615—17.5% | −2,054—−18.6% | |
| Capital expenditure | −109—−0.8% | −18—−0.1% | 0—0.0% | 0—0.0% | −35—−0.2% | −1,057—−4.3% | −1,147r−1,118—−2.1% | −893—−1.9% | −454r−455—−2.2% | −17—−0.2% | |
| Acquisitions, net of cash acquired | 0—0.0% | −10—−0.1% | −156—−1.0% | 0—0.0% | — | — | — | — | — | — | |
| Cash from investing activities | −109—−0.8% | −28—−0.2% | −156—−1.0% | 0—0.0% | −35—−0.2% | −1,057—−4.3% | −1,147—−2.1% | −1,244—−2.6% | −2,000r−2,000−335%−9.7% | 853—7.7% | |
| Shares issued | — | — | — | 0−100%0.0% | 4,407+2183%22.0% | 193—0.8% | 0—0.0% | — | — | 0—0.0% | |
| Cash from financing activities | 337+953%2.4% | 32—0.2% | −1,391−224%−8.7% | 1,121−74.3%6.9% | 4,370+33.5%21.8% | 3,274+6866%13.4% | 47—0.1% | −1,172−1085%−2.4% | 119r119−93.2%0.6% | 1,740—15.7% | |
| Exchange-rate effect on cash | 3.0—0.0% | −6.0—−0.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Change in cash | −176—−1.3% | −863−222%−5.5% | 706—4.4% | −764—−4.7% | −3,150—−15.7% | −5,083—−20.8% | −3,327−133%−6.2% | 10,143—21.0% | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 12,515−12.9%100% | 3,028−7.0%100% | 2,985−17.5%100% | 3,195−11.4%100% | 3,307*−14.9%100% | 3,256−15.8%100% | 3,620−8.4%100% | 3,606−9.9%100% | 3,884*+2.2%100% | 3,865—100% | 3,954—100% | 4,002—100% | 3,801*—100% | |
| Cost of revenue | 6,318−17.0%50.5% | 1,514−9.7%50.0% | 1,535−13.6%51.4% | 1,633−16.2%51.1% | 1,636*−25.9%49.5% | 1,677−19.6%51.5% | 1,776−15.2%49.1% | 1,948−9.4%54.0% | 2,207*+7.2%56.8% | 2,087—54.0% | 2,094—53.0% | 2,149—53.7% | 2,059*—54.2% | |
| Gross profit | 6,197−8.3%49.5% | 1,514−4.1%50.0% | 1,450−21.4%48.6% | 1,562−5.8%48.9% | 1,671*−0.4%50.5% | 1,579−11.2%48.5% | 1,844−0.9%50.9% | 1,658−10.5%46.0% | 1,677*−3.7%43.2% | 1,778—46.0% | 1,860—47.0% | 1,853—46.3% | 1,742*—45.8% | |
| Research and development | 73−43.4%0.6% | 19−20.8%0.6% | 18−64.0%0.6% | 18−40.0%0.6% | 18*−28.0%0.5% | 24−17.2%0.7% | 50+78.6%1.4% | 30−16.7%0.8% | 25*−37.5%0.6% | 29—0.8% | 28—0.7% | 36—0.9% | 40*—1.1% | |
| Selling, general and administrative | 6,941−15.3%55.5% | 1,618−11.6%53.4% | 1,733−10.0%58.1% | 1,862−12.9%58.3% | 1,728*−24.8%52.3% | 1,830−12.4%56.2% | 1,925−20.3%53.2% | 2,139−12.2%59.3% | 2,298*−11.3%59.2% | 2,090—54.1% | 2,415—61.1% | 2,437—60.9% | 2,591*—68.2% | |
| Selling and marketing | 2,593−10.0%20.7% | 613−11.3%20.2% | 644−10.3%21.6% | 673−7.9%21.1% | 663*−10.4%20.0% | 691−15.7%21.2% | 718−9.5%19.8% | 731−10.1%20.3% | 740*—19.1% | 820—21.2% | 793—20.1% | 813—20.3% | — | |
| General and administrative | 2,783−20.5%22.2% | 640−9.9%21.1% | 708−15.3%23.7% | 788−17.9%24.7% | 647*−35.0%19.6% | 710−4.1%21.8% | 836−33.0%23.1% | 960−4.2%26.6% | 996*—25.6% | 740—19.1% | 1,248—31.6% | 1,002—25.0% | — | |
| Operating income | −317—−2.5% | 377—12.5% | −301—−10.1% | −318−2991%−10.0% | −75*—−2.3% | −275—−8.4% | −131—−3.6% | 11—0.3% | −646*—−16.6% | −341—−8.8% | −583—−14.7% | −620—−15.5% | −889*—−23.4% | |
| Interest expense and finance costs | 223−53.7%1.8% | 0−100%0.0% | 1.0−99.2%0.0% | 93−38.4%2.9% | 129*+37.2%3.9% | 107−7.0%3.3% | 130—3.6% | 151—4.2% | 94*—2.4% | 115—3.0% | — | — | — | |
| Other non-operating income (expense) | — | −470—−15.5% | 469+261%15.7% | — | −129r−91*—−3.9% | −107—−3.3% | 130r−130—3.6% | −151—−4.2% | −94*−955%−2.4% | −115—−3.0% | −1.0—−0.0% | −2.0—−0.0% | 11*—0.3% | |
| Income before tax | −1,710—−13.7% | −93—−3.1% | −770—−25.8% | −643—−20.1% | −204*—−6.2% | −382—−11.7% | −261—−7.2% | −102—−2.8% | −740*—−19.1% | −456—−11.8% | −584—−14.8% | −622—−15.5% | −878*—−23.1% | |
| Income tax | 7.0—0.1% | 0—0.0% | 5.0—0.2% | 0−100%0.0% | 2.0*—0.1% | 0—0.0% | 0—0.0% | 7.0+16.7%0.2% | −14*—−0.4% | 0—0.0% | 0—0.0% | 6.0—0.1% | −9.0*—−0.2% | |
| Net income attributable to shareholders | −1,717—−13.7% | −93—−3.1% | −775—−26.0% | −643—−20.1% | −206*—−6.2% | −382—−11.7% | −261—−7.2% | −109—−3.0% | −726*—−18.7% | −456—−11.8% | −584—−14.8% | −628—−15.7% | −869*—−22.9% | |
| Earnings per share, basic | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | |
| Earnings per share, diluted | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | |
| Shares, weighted average (basic) | 226+22.7%— | 226+22.7%— | 205+11.3%— | 187+1.4%— | — | 184+1.1%— | 184+6.9%— | 184+13.0%— | — | 182—— | 172—— | 163—— | — | |
| Shares, weighted average (diluted) | 226+22.7%— | 226+22.7%— | 205+11.3%— | 187+1.4%— | — | 184+1.1%— | 184+6.9%— | 184+13.0%— | — | 182—— | 172—— | 163—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 308—4.8% | 308−19.2%4.8% | 266−70.0%4.1% | 309−61.9%4.6% | 278−38.8%4.0% | 381−61.1%5.4% | 886+85.7%11.1% | 812+22.7%10.5% | 454−65.5%5.7% | 979—11.7% | 477—5.4% | 662—7.8% | 1,317—14.3% | |
| Receivables | 346—5.4% | 346−14.6%5.4% | 348−36.1%5.3% | 391−9.1%5.8% | 402−23.0%5.8% | 405−4.0%5.8% | 545−14.7%6.9% | 430−15.2%5.5% | 522+21.1%6.6% | 422—5.0% | 639—7.2% | 507—6.0% | 431—4.7% | |
| Inventory | 3,965—61.6% | 3,965−2.8%61.6% | 3,965−6.0%60.8% | 3,902−10.7%58.0% | 4,087−16.5%58.7% | 4,080−18.7%58.3% | 4,216−19.0%53.0% | 4,368−24.1%56.3% | 4,897−13.4%61.8% | 5,020—59.8% | 5,206—58.6% | 5,756—68.0% | 5,655—61.5% | |
| Other current assets | 273—4.2% | 273+18.2%4.2% | 300+1.7%4.6% | 393+11.3%5.8% | 366−1.1%5.3% | 231−29.4%3.3% | 295−28.0%3.7% | 353−17.1%4.5% | 370−30.8%4.7% | 327—3.9% | 410—4.6% | 426—5.0% | 535—5.8% | |
| Current assets | 4,892—76.0% | 4,892−4.0%76.0% | 4,879−17.9%74.8% | 4,995−16.2%74.3% | 5,133−17.8%73.7% | 5,097−24.5%72.9% | 5,942−11.7%74.7% | 5,963−18.9%76.8% | 6,243−21.4%78.8% | 6,748—80.4% | 6,732—75.8% | 7,351—86.8% | 7,938—86.3% | |
| Property, plant and equipment | 302—4.7% | 302−13.5%4.7% | 319−12.1%4.9% | 329−9.6%4.9% | 344−13.8%4.9% | 349−28.8%5.0% | 363−45.5%4.6% | 364+14.1%4.7% | 399+5.3%5.0% | 490—5.8% | 666—7.5% | 319—3.8% | 379—4.1% | |
| Right-of-use (leased) assets | 148—2.3% | 148−63.9%2.3% | 215−54.4%3.3% | 282+9.7%4.2% | 347+269%5.0% | 410+406%5.9% | 472+4.7%5.9% | 257+84.9%3.3% | 94−43.7%1.2% | 81—1.0% | 451—5.1% | 139—1.6% | 167—1.8% | |
| Goodwill | 990—15.4% | 990−2.0%15.4% | 999−1.4%15.3% | 1,001+1.3%14.9% | 1,015+4.5%14.6% | 1,010+23.9%14.4% | 1,013+39.0%12.7% | 988+191%12.7% | 971+184%12.2% | 815—9.7% | 729—8.2% | 340—4.0% | 342—3.7% | |
| Other intangible assets | 55—0.9% | 55−32.9%0.9% | 62−29.5%1.0% | 68−24.4%1.0% | 76−18.3%1.1% | 82−20.4%1.2% | 88−17.0%1.1% | 90+23.3%1.2% | 93+19.2%1.2% | 103—1.2% | 106—1.2% | 73—0.9% | 78—0.8% | |
| Total assets | 6,434—100% | 6,434−8.0%100% | 6,521−18.0%100% | 6,722−13.4%100% | 6,962−12.2%100% | 6,995−16.6%100% | 7,950−10.5%100% | 7,761−8.3%100% | 7,927−13.8%100% | 8,391—100% | 8,886—100% | 8,466—100% | 9,200—100% | |
| Accounts payable | 813—12.6% | 813−33.0%12.6% | 1,059−26.5%16.2% | 1,080−27.8%16.1% | 1,044−45.8%15.0% | 1,214−35.6%17.4% | 1,440−37.6%18.1% | 1,496−39.2%19.3% | 1,925−16.6%24.3% | 1,886—22.5% | 2,307—26.0% | 2,460—29.1% | 2,309—25.1% | |
| Debt due within a year | 0—0.0% | 0−100%0.0% | 18−98.2%0.3% | 72−90.6%1.1% | 1,262+86.4%18.1% | 451—6.4% | 1,023—12.9% | 770—9.9% | 677—8.5% | — | — | — | — | |
| Current liabilities | 4,154—64.6% | 4,154−13.2%64.6% | 4,943−13.4%75.8% | 5,180−1.4%77.1% | 5,000−18.2%71.8% | 4,786−22.1%68.4% | 5,705−5.4%71.8% | 5,252−11.9%67.7% | 6,109−0.1%77.1% | 6,143—73.2% | 6,031—67.9% | 5,959—70.4% | 6,115—66.5% | |
| Long-term debt | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 387—5.6% | 504—7.2% | 208—2.6% | 498—6.4% | 0—0.0% | — | — | — | — | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 37−67.8%0.6% | 100+426%1.4% | 162—2.3% | 230−1.3%2.9% | 115+400%1.5% | 19−67.2%0.2% | 0—0.0% | 233—2.6% | 23—0.3% | 58—0.6% | |
| Total liabilities | 4,161—64.7% | 4,161−23.7%64.7% | 4,950−19.5%75.9% | 5,224−11.0%77.7% | 5,494−10.4%78.9% | 5,456−12.0%78.0% | 6,147−3.6%77.3% | 5,869−3.8%75.6% | 6,132−2.6%77.4% | 6,200—73.9% | 6,378—71.8% | 6,104—72.1% | 6,297—68.4% | |
| Retained earnings | −89,450—−1390% | −89,450—−1390% | −89,357—−1370% | −88,582—−1318% | −87,939—−1263% | −87,733—−1254% | −87,351—−1099% | −87,090—−1122% | −86,981—−1097% | −86,255—−1028% | −85,799—−966% | −85,215—−1007% | −84,587—−919% | |
| Shareholders' equity | 2,273—35.3% | 2,273+47.7%35.3% | 1,571−12.9%24.1% | 1,498−20.8%22.3% | 1,468−18.2%21.1% | 1,539−29.8%22.0% | 1,803−28.1%22.7% | 1,892−19.9%24.4% | 1,795−38.2%22.6% | 2,191—26.1% | 2,508—28.2% | 2,362—27.9% | 2,903—31.6% | |
| Total liabilities and equity | 6,434—100% | 6,434−8.0%100% | 6,521−18.0%100% | 6,722−13.4%100% | 6,962−12.2%100% | 6,995−16.6%100% | 7,950−10.5%100% | 7,761−8.3%100% | 7,927−13.8%100% | 8,391—100% | 8,886—100% | 8,466—100% | 9,200—100% | |
| Shares outstanding | 236—— | 236+27.9%— | 213+15.7%— | 193+5.0%— | 1840.0%— | 1840.0%— | 184+2.0%— | 184+12.9%— | 184+14.0%— | 184—— | 181—— | 163—— | 162—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 89−68.8%0.7% | 23*−25.8%0.8% | 22*−62.1%0.7% | 23−72.0%0.7% | 21*−81.6%0.6% | 31*−61.7%1.0% | 58*−23.7%1.6% | 82+30.2%2.3% | 114*+93.2%2.9% | 81*—2.1% | 76*—1.9% | 63—1.6% | 59*—1.6% | |
| Share-based compensation | 551+15.3%4.4% | 132*+6.5%4.4% | 148*+12.1%5.0% | 148+25.4%4.6% | 123*+18.3%3.7% | 124*+42.5%3.8% | 132*+257%3.6% | 118+293%3.3% | 104*+215%2.7% | 87*—2.3% | 37*—0.9% | 30—0.7% | 33*—0.9% | |
| Cash from operating activities | −170—−1.4% | 63*—2.1% | 20*−93.0%0.7% | 101—3.2% | −354*—−10.7% | −259*—−8.0% | 287*—7.9% | −81—−2.2% | −164*—−4.2% | −122*—−3.2% | −57*—−1.4% | −518—−12.9% | −114*—−3.0% | |
| Capital expenditure | −19—−0.2% | 0*—0.0% | −7.0*—−0.2% | −3.0—−0.1% | −9.0*—−0.3% | −11*—−0.3% | −49*—−1.4% | −40—−1.1% | −18*—−0.5% | 0*—0.0% | 0*—0.0% | 0—0.0% | — | |
| Acquisitions, net of cash acquired | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | −4.0*—−0.1% | — | — | — | −156*—−4.1% | |
| Cash from investing activities | −19—−0.2% | 0*—0.0% | −7.0*—−0.2% | −3.0—−0.1% | −9.0*—−0.3% | −11*−132%−0.3% | −49*—−1.4% | −40—−1.1% | −22*—−0.6% | 34*—0.9% | −40*—−1.0% | 0—0.0% | −156*—−4.1% | |
| Cash from financing activities | 118—0.9% | −18*—−0.6% | −54*—−1.8% | −68−114%−2.1% | 258*—7.8% | −234*−140%−7.2% | −167*—−4.6% | 480—13.3% | −335*—−8.6% | 590*—15.3% | −87*—−2.2% | −136—−3.4% | −56*—−1.5% | |
| Exchange-rate effect on cash | −2.0—−0.0% | −3.0*—−0.1% | −2.0*−167%−0.1% | 1.0—0.0% | 2.0*—0.1% | −1.0*—−0.0% | 3.0*—0.1% | −1.0—−0.0% | −4.0*—−0.1% | 0*—0.0% | −1.0*—−0.0% | −1.0—−0.0% | 0*—0.0% | |
| Change in cash | −73—−0.6% | 42*—1.4% | −43*−158%−1.4% | 31−91.3%1.0% | −103*—−3.1% | −505*−201%−15.5% | 74*—2.0% | 358—9.9% | −525*—−13.5% | 502*—13.0% | −185*—−4.7% | −655—−16.4% | −326*—−8.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where CV Sciences, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at CV Sciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Dowling | $419 K | $423 K | $308 K | — |
| 2024Mr. Dowling | $458 K | $241 K | $343 K | $100 |
| 2023Mr. Dowling | $403 K | $314 K | $273 K | $133 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at CV Sciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 8 · Agreement ended 1 · New debt 2 · Unregistered share sale 3 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How CV Sciences, Inc. compares in Pharmaceutical
- Revenue$14 M · higher than 7% of 324
- Net margin-15.8% · higher than 16% of 313
- Revenue growth-12.2% · higher than 12% of 107
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CV Sciences, Inc.🇺🇸 | $20 M | — | -15.8% | -12.2% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 7, 2022 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CV Sciences, Inc.? Verify and update this profile — free
Show CV Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.